Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EPS (Weighted Average and Diluted) (2021 - 2025)

Sunshine Biopharma's EPS (Weighted Average and Diluted) history spans 5 years, with the latest figure at -$0.44 for Q1 2025.

  • For Q1 2025, EPS (Weighted Average and Diluted) rose 78.0% year-over-year to -$0.44; the TTM value through Mar 2025 reached -$2.34, up 63.35%, while the annual FY2024 figure was -$7.32, 97.92% up from the prior year.
  • EPS (Weighted Average and Diluted) reached -$0.44 in Q1 2025 per SBFM's latest filing, up from -$3.08 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $0.26 in Q4 2021 to a low of -$97.47 in Q4 2023.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$9.37, with a median of -$0.34 recorded in 2025.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 6193.06% in 2023, then soared 96.84% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at $0.26 in 2021, then crashed by 706.43% to -$1.55 in 2022, then plummeted by 6193.06% to -$97.47 in 2023, then surged by 96.84% to -$3.08 in 2024, then surged by 85.69% to -$0.44 in 2025.
  • Per Business Quant, the three most recent readings for SBFM's EPS (Weighted Average and Diluted) are -$0.44 (Q1 2025), -$3.08 (Q4 2024), and -$2.0 (Q1 2024).